NovelBeam Technology(SH:688677)2023-06-26 16:00Financial Performance - The company's operating revenue for 2022 reached ¥476,821,312.39, representing a year-on-year increase of 53.97%[24]. - Net profit attributable to shareholders increased by 55.07% to ¥182,569,601.64, while the net profit excluding non-recurring gains and losses rose by 79.44% to ¥168,680,318.38[24][27]. - The cash flow from operating activities remained stable, with a net amount of ¥104,375,771.45, showing a slight increase of 0.36% compared to the previous year[24][27]. - Total assets grew by 17.92% to ¥1,393,534,642.98, and net assets attributable to shareholders increased by 11.75% to ¥1,219,243,201.94[24][27]. - Basic earnings per share rose to ¥2.10, reflecting a 48.94% increase from the previous year[25]. - The company's operating income for the fourth quarter was 137,148,352.30 RMB, while the net profit attributable to shareholders was 42,692,243.69 RMB, indicating a stable performance despite fluctuations in net profit due to factors such as share-based payments and exchange rate losses[30][31]. Dividend and Capital Structure - The company plans to distribute a cash dividend of RMB 8.00 per 10 shares, totaling RMB 69,314,761.60 (including tax) based on the remaining shares after buybacks[5]. - The company intends to increase its capital reserve by issuing 4 additional shares for every 10 shares held, resulting in an increase of 34,657,381 shares, raising the total share capital to 121,637,381 shares[5]. - The company has not experienced any changes in its total share capital from the announcement date to the equity distribution registration date[6]. Audit and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for external guarantees[9]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a commitment to investors[8]. Research and Development - The company's R&D expenditure accounted for 12.56% of operating revenue, a decrease of 0.79 percentage points compared to 2021[25]. - Research and development investment in 2022 was 59.90 million yuan, a 44.88% increase from the previous year, constituting 12.56% of operating revenue[40]. - The company applied for 42 new patents and obtained 33 new patents during the reporting period[118]. - The company has a cumulative total of 156 patent applications, with 96 patents granted, reflecting its commitment to innovation[119]. - The company has developed a dual-channel 3D fluorescence endoscope technology suitable for 10mm laparoscopic systems, enhancing surgical capabilities[115]. Market and Sales - The company achieved dual growth in both domestic and international markets while expanding its optical business and related products alongside the rapid growth of its medical endoscope business[38]. - The company plans to increase the promotion of its complete system products domestically, despite facing competition from established imported brands[136]. - The total sales revenue for the top five customers reached 375.19 million RMB, accounting for 78.69% of the annual sales total[157]. - Sales to Customer 1 amounted to 295.44 million RMB, representing 61.96% of the annual sales total, with a year-on-year increase of 67.41%[158]. Production and Supply Chain - The company has increased inventory to mitigate the impact of extended delivery times due to global supply chain disruptions[54]. - The company implements a supply chain management system that includes supplier grading and continuous evaluation to ensure quality[51]. - The production of medical endoscopes follows ISO 13485 standards, ensuring compliance with quality management requirements[54]. - The company has seen an increase in procurement from new suppliers due to increased production of new products[163]. Technological Innovation - The company has established four core technology platforms: optical technology, precision machinery technology, electronic technology, and digital image technology[76]. - The company has successfully implemented multi-spectral LED illumination technology in endoscope systems, which can also be extended to clinical diagnostic applications[81]. - The company has developed a leading fluorescence endoscope that integrates fluorescence technology with endoscopic technology, opening new applications in the medical field[74]. - The company is integrating deep learning-based intelligent image recognition technology into its next-generation intelligent surgical endoscope system[75]. Future Plans - The company plans to accelerate the development of medical endoscope series products to expand its existing product line[182]. - The company aims to enhance its competitive edge in fluorescence endoscope products by continuously upgrading existing models and developing new ones[184]. - The company is committed to strengthening talent development and improving employee cohesion through a competitive compensation system[192]. - The company will complete the registration and launch of the second generation 4K fluorescence endoscope imaging system and fog-free imaging system, establishing a nationwide distribution channel[194].